Skip to main content

The potential of Prosigna

Thank you

We would like to thank you for your participation in today’s event and encourage you to attend of next Prosigna live programs.

Contributors

  • P. Kelly Marcom, MD | Medical Director-Breast Cancer, Veracyte

    Dr. P. Kelly Marcom joined Veracyte in June, 2021 as the Medical Director for Breast Cancer. He came from Duke University, where he was Professor of Medicine and Director of the Duke Multidisciplinary Breast Cancer Program. After undergraduate education at Texas A&M University and medical school at Baylor College of Medicine, he moved to Duke University for postgraduate training in internal medicine and hematology/oncology, completing training in 1995. He joined the medical oncology faculty in 1995 doing basic research on cell cycle control and as a member of the breast group in 1997 as a clinical and translational researcher. He established the Duke Hereditary Cancer Clinic in 1998 and led it until 2016, when he became the breast program director. Nationally, he has been a member of the National Comprehensive Cancer Network guidelines panels for Breast Cancer and Breast/Ovarian Genetics and served as track leader for the Cancer Genetics Education planning committee for ASCO in 2017. He was an active member of many clinical/translational programs, including CALGB, the Translational Breast Cancer Research Consortium, and Duke Breast Cancer SPORE grants. His research interests have focused on improving the management of breast cancer with an overall theme of using genetic and genomics to guide personalized risk assessment and treatment.

June 16, 2022
Thu 6:00 PM CEST

Duration 0H 45M

This live web event has ended.

For Technical Support
(888) 705-6002
+1 (858) 201-4136*
*for callers residing outside of the United States